Fig. 1

Quantification of plasma IFN-γ in SACC and OSCC patients and comparison the sensitivity of SACC cells and OSCC cells to IFN-γ. a Plasma IFN-γ levels were determined by ELISA in SACC samples (n = 25) and OSCC samples (n = 23) (P = 0.058 6). b Representative hematoxylin and eosin stained images and expression levels of PD-L1 in SACC (n = 14) and OSCC samples (n = 17) were determined by immunohistochemical staining. Patients with undetectable plasma IFN-γ were included in IFN-γ low group and those with detectable plasma IFN-γ were included in IFN-γ high group. Scale bar: 20 μm. c H-score of PD-L1 of SACC and OSCC samples. d Western blot analysis of IFN-γ/STAT1/PD-L1 pathway on SCC25, CAL27, and SACC-83 with or without IFN-γ treatment for 18 h (left, n = 3). Quantification of the western blotting data (right, normalized to GAPDH, n = 3). e mRNA expression of PD-L1 in SCC25, CAL27, and SACC-83 upon IFN-γ treatment for 12 h (n = 3). f CCK8 assay showing the effect of IFN-γ treatment on proliferation of CAL27, SCC25, and SACC-83 for 48 h (n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.000 1